Bordetella pertussis causes whooping cough, a severe and prolonged respiratory disease that results inhas high morbidity and mortality rates, particularly in developing countries. The number incidence of whooping cough cases is increasing in many countries despite high vaccine coverage. Causes for the re-emergence of the disease include the limited duration of protection conferred by the acellular pertussis vaccines (aP)s and pathogenic adaptations that involve antigenic divergence from vaccine strains. Therefore, current vaccines therefore need to be improved. In the present study, we focused on five autotransporters: namely SphB1, BatB, SphB2, Phg, and Vag8, which were previously found to be expressed by B. bronchiseptica during the course of infection in rats and examined their protective efficiencies as vaccine antigens. The passenger domains of these proteins were produced in recombinant forms and used as antigens. An intranasal murine challenge assay showed that immunization with a mixture of SphB1 and Vag8 (SV) significantly reduced bacterial load in the lower respiratory tract and a combination of aP and SV acts synergistically in effects of conferring protection against B. pertussis infection, implying that these antigens have potential as components to for improvinge th the currently available acellular pertussis vaccine.
. A recent study demonstrated that although aPs do suppress development of severe clinical symptoms, they do not prevent colonization of the upper respiratory tract and consequently do not adequately reduce circulation in the population, and thus transmission of B. pertussis (14) . Moreover, other studies have suggested that B. pertussis has become acclimated to aP as a result of alterations in its antigenicity. For example, antigenically divergent strains such as the B. pertussis ptxP3 lineage, which produces larger amounts of several virulence factors, have reportedly emerged (15, 16) . Strains that do not produce pertactin, a component of most aPs, are being increasingly isolated from patients with whooping cough (17) (18) (19) . These phenomena indicate that wPs and/or aPs need to be improved to overcome the above-described issues.
In the present study, we propose candidates for novel protective antigens that may support improvements in aP. We have previously developed a novel method termed IVET-IP for identifying ivi genes expressed during infection with B. bronchiseptica, which is closely related to B. pertussis (20) . By using IVET-IP, we identified 173 ivi genes of B. bronchiseptica colonizing the rat trachea. We then selected five of these ivi genes (sphB1, batB, sphB2, phg and vag8) that encode autotransporter proteins that are shared with B. pertussis as protective antigen candidates. Next, we evaluated the protective efficacies of these antigens in an intranasal murine challenge assay on B. pertussis infection. Immunization of mice with a mixture of the five antigens conferred significant protection against B. pertussis infection. B. pertussis infection induced production of antibodies against SphB1 and Vag8. Immunization of mice with a mixture of SphB1 and Vag8 conferred synergistic protection against B. pertussis infection in the combination of aPs. Our results suggest that these two antigens have potential as components of an improved pertussis vaccine.
MATERIALS AND METHODS

Bacteria
B. pertussis 18323 and Tohama I strains were kindly provided by the Kanonji Institute of BIKEN Foundation and maintained in our laboratories. B. pertussis grown on Bordet-Gengou agar containing 1% glycerol, 20% defibrinated horse blood and 10 mg/mL ceftibuten at 37°C for 3 days was collected, suspended in StainerScholte liquid medium (21) at an OD 650 value of 0.2 and incubated with agitation for 12-14 hr. The numbers of CFUs were estimated from OD 650 values of fresh cultures according to the following equation: 1.0 OD 650 ¼ 3.0 Â 10 9 CFU/mL.
Construction of expression vectors
pCold II vector was purchased from Takara Bio (Kyoto, Japan). The poly-HAT gene was synthesized by PCR using the oligo primers HAT-F and HAT-R (22, 23) . The backbone region of the pCold II vector was amplified by inverse PCR with pCold II vector as a template and a combination of the primers pCold II (-His)-F and pCold II (-His)-R. The DNA fragment of the HAT gene was inserted into the vector backbone using an In-Fusion HD cloning kit (Clontech Laboratories, Palo Alto, CA, USA). DNA fragments of the candidate antigens were amplified by PCR with appropriate primers and then cloned into pCold II or pCold II-HAT vectors. The primers used in this study are listed in Table S1 and the plasmids in Table S2 .
Production of recombinant proteins in Escherichia coli
E. coli BL21 (DE3) harboring each expression vector was cultured in LB broth containing 50 mg/mL of ampicillin at 37°C overnight. Cultured E. coli BL21 (DE3) was inoculated into LB medium containing 50 mg/mL of ampicillin to achieve an OD 600 of 0.1 and incubated with shaking at 37°C to an OD 600 of 0.5 followed by at 15°C overnight in the presence of 1 mM isopropyl b-D-1-thiogalactopyranoside. The bacteria were centrifuged, suspended in 50 mM sodium phosphate buffer pH 8.0 containing 300 mM NaCl and 10 mM imidazole and lysed by an ultrasonic treatment with a probe-type sonicator. After centrifugation, the recombinant proteins (SphB1, BatB, SphB2 or Phg) in the supernatant were purified by affinity chromatography with nickelnitrilotriacetic acid-agarose (Sigma-Aldrich, St Louis, MO, USA). Vag8, which was produced in E. coli as insoluble aggregates, was dissolved in 50 mM sodium phosphate buffer pH 8.0 containing 300 mM NaCl, 8 M urea and 10 mM imidazole and purified as described above. Urea in the purified Vag8 preparation was gradually removed by dialysis against 50 mM sodium phosphate buffer pH 8.0 containing 300 mM NaCl and urea of decreasing concentrations (6M, 4M, 2M, 1M, 0.5M, 0M). Protein concentrations were determined using Micro BCA (Thermo Fisher Scientific, Pittsburgh, PA, USA). 
Immunization of mice
Intranasal challenge assay
An intranasal challenge assay was performed as described previously with some modifications (24) . Seven-week-old female Balb/c mice were anesthetized by an intraperitoneal injection of midazolam (0.5 mg/kg), medetomidine (0.03 mg/kg) and butorphanol (0.5 mg/kg) and intranasally inoculated with 5 Â 10 6 CFU/50 mL of B. pertussis 18323. Two hours and four and eight days after inoculation, mice were killed by an intraperitoneal injection of pentobarbital sodium and their lungs and tracheae aseptically excised. Individual lungs were homogenized in 1 mL of 137 mM NaCl, 2.7 mM KCl, 
ELISA
Ninety-six-well polystyrene plates were coated with 1.0 mg/well of each recombinant protein, standard PT (JNIH-5, NIBSC) or standard FHA (JNIH-4, NIBSC) at 4°C overnight, then blocked with 300 mL per well of D-PBS (À), containing 0.5% BSA (Thermo Fisher Scientific) at 37°C for 1 hr. Serum samples were ten-fold serially diluted in D-PBS (À), and goat secondary antimouse IgG-HRP (Cappel) was then sequentially allowed to react at 37°C for 1 hr. After each step, the plates were washed five times with D-PBS (À) containing 0.05% Tween 20. One hundred microliters of the colorimetric TMB (3, 39, 5, 59-tetramethylbenzidine) peroxidase enzyme immunoassay substrate (Wako, Osaka, Japan) was added to each well, after which the plates were incubated at RT for 30 min. The reactions were stopped by adding 100 mL/well of 1.0 N H 2 SO 4 . Optical density was read on a Multi-Detection Microplate Reader (DS Pharma Biomedical, Osaka, Japan) at 450 nm.
Immunoblotting
Recombinant proteins (2.0 mg each) were suspended in 100 mL of SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, containing 6% glycerol, 2% SDS, 12.5 mM dithiothreitol and 0.01% bromophenol blue) and subjected to 12.5% polyacrylamide SDS-PAGE followed by electrotransfer to a polyvinylidene difluoride membrane (Millipore Billerica, MA, USA). The membranes were blocked in block buffer (5% skim milk in 50 mM TBS-T) overnight at 4°C. The membranes were then incubated at RT for 1 hr with mouse anti-SBSPV (1:3000) serum followed by frequent washing with TBS-T. Subsequently, secondary antibody incubation was performed at RT for 1 hr using goat anti-mouse IgG-HRP (1:1000; Cappel, West Chester, PA, USA) antibody, followed by frequent washing with TBS-T. Signals were detected with an Immobilon Western (Millipore).
Anti-B. pertussis serum
Anti-B. pertussis serum was obtained as follows. B. pertussis Tohama I was cultured for 24 hr in Stainer-Scholte medium, then heat-inactivated at 56°C for 30 min and fixed with 0.5% formalin in D-PBS (À) at 4°C overnight. The fixed bacteria were resuspended in D-PBS (À) after centrifugation and used as Bp-antigen. Twelve-week-old female Kbl:JW rabbits (Kitayama Labs, Nagano, Japan) were injected s.c. with Bp-antigen (equivalent to 1.0 Â 10 8 CFU) emulsified in Freund's complete adjuvant and subsequently with the same doses of Bp-antigen emulsified in Freund's incomplete adjuvant one week, two weeks and six weeks after the first injection. Three days after the final injection, the rabbits were bled and their sera collected and used as anti-Bp in immunocytochemistry.
Immunocytochemistry on the bacterial surface
Immunocytochemistry was performed as described previously with some modifications (25) . B. pertussis was obtained as described above, suspended in D-PBS (À) after centrifugation and then spotted on glass slides. Bacterial spots were fixed in 4% paraformaldehyde, blocked by D-PBS (À) containing 10% FCS, treated with anti-SBSPV mouse antiserum (1:1000) or anti-Bp rabbit antiserum (1:1000) at 4°C overnight, and subsequently with Alexa Fluor 488-conjugated goat anti-mouse IgG (1:200; Invitrogen, Carlsbad, CA, USA) or Alexa Fluor 546-conjugated goat anti-rabbit IgG (1:200; Invitrogen) antibody at RT for 2 hr in the dark. After each step, the glass slides were washed three times with D-PBS (À). Samples were mounted in ProLong Diamond Antifade Mountant with DAPI (Thermo Fisher Scientific) and imaged using a microscope equipped with FV1000 (Olympus, Tokyo, Japan). The images obtained were processed using ImageJ (NIH) and Photoshop (Adobe).
Statistical analysis
Differences between results obtained in the experiments were evaluated by Student's t-test. P < 0.05 was taken to denote significance.
Ethics statement
All animal experiments were approved by the Animal Care and Use Committee of the Research Institute for Microbial Diseases, Osaka University and carried out according to the Regulations on Animal Experiments of Osaka University.
RESULTS
Production of recombinant proteins of in vivo-expressed autotransporters
We previously identified 173 ivi genes expressed in B. bronchiseptica RB50 colonizing the rat trachea using a newly developed IVET-IP analysis (20) . Of these, we focused on five genes (sphB1, batB, sphB2, phg and vag8) as candidates for protective antigens against Bordetella infection. All these genes encoding autotransporters (26) are conserved in B. pertussis Tohama I (Table 1) . SphB1, BatB, SphB2, Phg and Vag8 are autotransporters and consist of N-terminal passenger and C-terminal autotransporter domains. In these proteins, the passenger domains are exported to the extracellular milieu from outer membrane pores organized with the autotransporter domains (26, 27) . Therefore, we generated recombinant proteins of the passenger domain expressed in E. coli (Fig. 1a,b) . Antiserum (anti-SBSPV) raised by immunizing mice with a mixture of recombinant proteins (SphB1, BatB, SphB2, Phg and Vag8; SBSPV) recognized each recombinant protein, as judged by immunoblotting (Fig. 1c) . Immunofluorescence microscopy showed that anti-SBSPV dominantly recognized the cell surface of B. pertussis (Fig. 1d) . These results suggest that SBSPV retains the antigenicity of each protein and that at least some of the antigens are extracellularly exported and recognized by anti-SBSPV, indicating that SBSPV includes potential protective antigens.
Protective effects of SBSPV against B. pertussis infection in a mouse model
The above-described results suggest the potential of SBSPV as components of a prophylactic vaccine against B. pertussis infection. To investigate this possibility, we subjected mice immunized with SBSPV to an intranasal B. pertussis challenge and measured antibody titers in the sera of the SBSPV-immunized mice. We confirmed these antigen-specific antibodies were not present in preimmune serum. ELISA revealed that all antigen candidates raised antigen-specific IgGs (Fig. 2a) . We recovered greater numbers of bacteria from the lungs and tracheae of control mice than from those of SBSPVimmunized mice (Fig. 2b-g ). These results suggest the potential of SBSPV as components of a vaccine that exerts prophylactic effects against B. pertussis infection.
Antibody production against SphB1 and Vag8 in B. pertussis-infected mice
To evaluate production of antibodies for each autotransporter after B. pertussis infection, we performed ELISA using B. pertussis-infected mouse sera obtained on Day 42 post-infection. We detected antibodies against SphB1 and Vag8, but not against BatB, SphB2 or Phg, in Parkhill et al. (26) this assay system (Fig. 3a-e We detected antigen-specific IgGs in the sera of SphB1, Vag8 and aP-immunized mice (Fig. S1 ) and confirmed that pre-existing antigen-specific antibodies were not present in pre-immune serum. We recovered significantly fewer bacteria from mice immunized with SphB1 or Vag8 than from control mice (Fig. 4a,b) . Immunization with a mixture of SphB1 and Vag8 (SV) conferred greater protection than individual immunizations. Furthermore, we examined the synergistic effects of immunization by the combination of these protective antigens and aP against B. pertussis infection by subjecting mice immunized with recombinant SphB1, Vag8 or SV, and aP to intranasal B. pertussis challenge. We compared our results with those from mice immunized with either SphB1, Vag8, SV or aP and found that immunization with aP þ SphB1, aP þ Vag8 and aP þ SV raised antibodies against each antigen component as judged by ELISA (Fig. S1 ). We recovered significantly fewer bacteria from the lungs of mice immunized with aP þ SV than from those of mice immunized with aP (Fig. 4a) ; however, in contrast, a recovered similar number of bacteria from the tracheae of mice immunized with aP (Fig. 4b) . These results suggest that the combination of aP and SV has synergistic effects on persistence of bacteria, at least in the lung.
DISCUSSION
In the present study, we examined the possibility of the autotransporters SphB1, BatB, SphB2, Phg and Vag8 conferring protection against B. pertussis infection in mice. These transporters have are reportedly expressed by B. bronchiseptica colonizing the rat trachea (20) . B. pertussis infection induces production of antibodies SphB1 and Vag8 among five in vivo-expressed autotransporters. Immunization with SphB1, Vag8 and SV, a mixture of autotransporters, confers some protection against respiratory infection by B. pertussis and a combination of aP and SV acts synergistically in conferring protection. Protective effects of SphB1 and Vag8 are consistent with those previously reported (28) . The synergism in protective effects observed with the addition of SV suggests that these two autotransporters could be additional components for improving the current vaccine. Expression of nearly all virulence factors of B. pertussis, including the antigens present in aP, is positively regulated by the two-component sensory transduction system BvgAS (29, 30) . Bvg-activated genes are generally associated with virulence or evasion of host defense. Previous studies have shown that expression of both SphB1 and Vag8 is strongly enhanced in the BvgASactivated state (31) (32) (33) . Our present data support the contention that proteins that are present in the BvgASactivating phase could be suitable new antigens for enhancing the protection conferred by pertussis vaccine.
SphB1 contains a serine protease domain for cleaving FhaB adhesin on the cell surface, thereby generating a mature FHA protein that is released into the extracellular milieu (34, 35) . Deletion of the sphB1 gene has been found to markedly attenuate the ability of B. pertussis to infect mice and to enhance phagocytosis (36, 37) . Vag8 directly binds and recruits C1 esterase inhibitor on the bacterial surface and disruption of vag8 significantly diminishes resistance to serum killing (38, 39) . Antibodies to these proteins may facilitate phagocytosis through opsonization or deposition of complement factors on the bacterial surface. Alternatively, the antibodies may neutralize the biological activity of these antigens. The synergistic protective effects conferred by combined immunization imply that the protective mechanisms of SphB1 and Vag8 differ from those of aP. Further analyses are needed to elucidate the protective activity of SphB1 and Vag8 and the mechanism(s) responsible for that protection.
To develop a new effective pertussis vaccine, both a novel adjuvant system and route of vaccine administration need to be investigated as well as novel probable antigens. Because wP immunization and natural B. pertussis infection induce Th1-type immune responses, many researchers have stated that an adjuvant that induces Th1-type immunity is preferable for protection against B. pertussis infection. Previous studies have reported that the TLR9 agonist CpG promotes robust cell-mediated immunity and confers efficient protection against B. pertussis infection (40) (41) (42) . In addition, a nasal inoculation route for vaccines may be preferable for inducing mucosal immunity in the respiratory system. We are currently conducting further studies to examine the protective efficacies of the antigens of both SphB1 and Vag8 together with the administration route and effective adjuvants to add to a vaccine. 
SUPPORTING INFORMATION
Additional supporting information may be found in the online version of this article at the publisher's web-site. Table S1 . Primers used in this study Underlined sequences are reverse-complement sequences for in-fusion cloning. Table S2 . Plasmids used in this study Domains deleted specify the amino acid locations of predicted signal peptide (based on SignalP 3.0) and other targeting domains.
